- Tytuł:
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology December 2021 22(12):1752-1763
Czasopismo naukowe